Experimental drug DT-109 shows promise in reversing severe fatty liver disease
UNVERIFIED·Primary source · Science Daily
An experimental drug, DT-109, has reversed severe fatty liver disease (MASH) in animal models by restoring gut health.
The drug reduces Clostridium perfringens overgrowth and ammonia production, strengthening the intestinal barrier.
Clinical trials are the next step for this potential treatment for metabolic and cardiovascular disorders.
Key Facts
01
01 — What / Thesis
Experimental drug DT-109 shows promise in reversing severe fatty liver disease
02
02 — Who / Subject
Eugene Chen, Jifeng Zhang, Michigan Medicine
03
03 — Where / Locus
USA
04
04 — When / Temporality
July 2026
AI Verification Note
This article is generated by cross-referencing multiple sources and official announcements. Parts relying solely on testimony or reporting are reflected in the confidence score; content and assessment are updated as new information is confirmed.
